Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This the last I can see .
Published 10 April, 2018 2:20 pm
Rupert Hargreaves
One ‘secret’ growth stock I’d buy alongside this FTSE 100 growth monster
Motif is a high risk, high reward secret growth stock and to reduce the risk of holding it in your portfolio, I would buy it alongside Shire (LSE: SHP).
This hidden growth stock is gearing up to become the next FTSE 100 (INDEXFTSE:UKX) growth champion.
When my Foolish colleague Kevin Godbold last covered Motif Bio (LSE: MTFB) at the end of last year he concluded that, after a recent fundraising supported by a specialist pharmaceutical lender, the firm’s outlook had improved significantly.
Nearly four months on and it looks to me as if this assessment remains accurate.
About to pay off
Motif raised $20m in debt financing from Hercules Capital, a firm specialising in customised debt financing for companies in life sciences and technology-related markets, at the end of last year. This additional cash has helped the company push forward with the development of its flagship iclaprim treatment.
Iclaprim is designed to fill a gap in the traditional antibiotic market by providing a standard of care not currently available to patients who have other health issues, specifically, kidney problems. The size of the potential market for this treatment is growing as more and more people become exposed to issues that may impact kidney function, such as obesity and diabetes.
2018 and 2019 will be a transformational year as the company seeks to get this treatment approved for sale by the US Food and Drugs Administration. It has already met FDA standards in Phase 3 clinical trials conducted throughout 2017, so management is hopeful that it won’t be long before it can start booking revenue from sales.
However, the firm is facing the prospect of a cash crunch.
Motif is generating no revenue and lost a total of $44.8m last year. With cash and cash equivalents of $22.7m at the end of December 2017 (and $15m of the $20m drawn down from debt financing), the firm has less than six months of cash left before new funding is required.
Indeed, today’s full-year earnings release from the company states: “The Group will be required to raise additional capital within the next year.” Still, with Iclaprim on the verge of being approved by regulators, it looks as if the risk/reward is skewed in investors’ favour.
More predictable outlook
Motif is a high risk, high reward .
I made three buys ( D ) April to May 2017.
Made a little back with a small trade Bursary 2019 .
Total loss around 260%
Wuckfit mine have been removed today ( D )
jam2morrow posted below 22/5/22
I would like to think there will be some form of closure in this tax year. It has been previously posted that these shares can be classed as negligable value for tax purposes.......but I didn't have taxable disposals last year to be able to confirm this.
I see the italian was also a holder .
Motif Bio: Lessons from a failed pharma
Catastrophic pharmaceutical failures can provide interesting entry points to investors who know how to trade them
June 16, 2021
By Michael Taylor
Motif Bio failed to get its novel antibiotic approved in the US leading to the eventual collapse of the company
Investors have voted to reject a reverse takeover that might have rescued the company, but given too much to the existing directors
Got the "This company is now worthles" mesage fom HL today.. I wonder if GL got one as wel!
Same @ISA......we haven't had an RNS so i wonder whats changed. Not a lot of use to me this tax year as i don't have any taxable gains that i can discount against MTFB. Does anybody know if we can use this 'deemed worthless' category in the next tax year/ future tax years ?
Just got the above title email in my inbox, referring to a corporate action, from ii.
Had forgotten all about this disaster!
Thanks Mark. I guess you know that a new company has been set up? Motif Bio Services Ltd
https://find-and-update.company-information.service.gov.uk/company/13924547
The purpose of the company is seemingly to take on the remnants of 'the asset' that was rights to any income that may come from either a sale of Iclaprim or proceeds of sales of the drug that amount to anything above 'x' amount. Difficult to say what x might be as there are wolves asking for loans back. And no sight of any buyer or developer stepping in yet.
Last I heard is that they would do the right thing in distributing income rightfully to original shareholders should it ever happen. But I certainly wouldn't hold my breath. The problem is that we need a true representative of shareholders on the board of the new Services company to ensure that the ceo of the new outfit does not stray from legal boundaries. Which I fear, through lack of communication, may have already happened, even if inadvertently.
Just my understanding. Happy to be corrected if anyone has other info.
GS
Thanks Mark. And so it ends
doubt there were many expecting anything different.water under the bridge
This.
https://twitter.com/mark197315/status/1576138488717934592?s=46&t=Aj3TC1Wm2u5Dff2VGaJ6DA
What was the post below Mark? Doesn’t work now.
What is there to hear? The company has no assets/money, directors gone, it's just an empty shell company gathering dust for eternity.
Anyone heard anything of late?
I would like to think there will be some form of closure in this tax year. It has been previously posted that these shares can be classed as negligable value for tax purposes.......but I didn't have taxable disposals last year to be able to confirm this
Wookie.....
Have no fear, your shares should one day be worth £thousands [possibly £millions ;-)....]
We long suffering holders have it on good faith from Kettle & his Krew that they are best buddies with the 'Board' and , following in-depth discussions , we can all look forward to seeing Motif rise again, like the proverbial "Phoenix from the Ashes"..........
Just don't hold ya breath !!!
GLA
can I get rid of this from my trading account? My 144,310 shares are still showing in my trading account with a value of £432 but of course I can't sell them. When will the company be dissolved?
Hope everyone who has shares here is ok and has made some money back elsewhere.
Mr Stephen Austin
Motif Bio Services
39 Temple Fortune Hill,
London,
United Kingdom,
NW11 7XP
Stephen Austin
Motif Bio
LANGLEY HOUSE PARK ROAD
LONDON
ENGLAND
N2 8EY
Now why would Mr Austin set up that company of the above name on the 18th February 2022 and the take over Motif Bio from Mr Gold and Me Lumsden?
Sounds like they will transfer Motif Bio into Motif Bio Services and therefore doesn’t look like Gold and Lumsden bankrupted the company so they can carry on with their greed escapades at the expense of shareholders as Directors
I would call Mr Austin at Plumtree and ask him for his plans if you care about your money and influence here
+4402071835860
I see Mr Gold and Mr Lumsden have resigned from the 1st March (I guess taking a company off NASDAQ and bankrupting doesn’t look good on the CV) and have handed over to Stephen Austin (Investment Banker in the loosest sense) Plumtree Capital is the location of his main work and Sharon Cohen.
I see Stephen was also with Amphion Innovations so is well versed in Motifs catastrophic failure.
I guess this is a step away from the insolvency we all knew was coming.
Nice update from the two cowards. Never expected anything else to be honest
NO no no noooo....
we have it on good authority from Kettle & his Krew that this will rise ......
like a Phoenix from the Ashes !!
Just don't hold ya breath.....
;-)
Am I right in assuming that this Share is now DEAD? I was hoping that something was going to happen, but it doesn't seem likely now
There will be some rocking going on in Heaven tonite !!!
Meatloaf & Steinman reunited.
R.I.P
(Rocking In Paradise)
.................................................................
..... https://youtu.be/NUcEVkfuZ9U .....
..... https://youtu.be/RTOtCoVqgbs .....
..... https://youtu.be/_wO8toxinoc .....
..... https://youtu.be/mVMD-cTs6kc .....
........................................................................
Thanks, I vaguely remember it being sold for $1 but couldn't remember who to.
Orange Avenue Technologies acquired it for $1.
https://www.lse.co.uk/rns/MTFB/update-re-motif-biosciences-inc-1vqmwksotj9bc02.html